Litcius/Paper detail

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, Giovanna Esposito, Claudio Dazzi, Luigi Cavanna, Marco Angelo Burgio, Francesco Rosetti, Simona Rizzato, Floriana Morgillo, Saverio Cinieri, Antonello Veccia, Maximilan Papi, Giuseppe Tonini, Vittorio Gebbia, Serena Ricciardi, Daniele Pozzessere, Alessandra Ferro, Claudia Proto, Raffaele Costanzo, M. D’Arcangelo, Manuela Proietto, Piera Gargiulo, Raimondo Di Liello, Laura Arenare, Filippo de Marinis, Lucio Crinò, Fortunato Ciardiello, Nicola Normanno, Ciro Gallo, Francesco Perrone, Cesare Gridelli, Alessandro Morabito

2022Journal of Thoracic Oncology68 citationsDOIOpen Access PDF

Topics & Concepts

ErlotinibMedicineBevacizumabInternal medicineHazard ratioOncologyRandomized controlled trialErlotinib HydrochlorideConfidence intervalRamucirumabRashEpidermal growth factor receptorCancerChemotherapyLung Cancer Treatments and MutationsAdvanced Breast Cancer TherapiesColorectal Cancer Treatments and Studies